The global wearable injectors market size was valued at USD 2.9 billion in 2016 and is expected to grow at a CAGR of 16.4% during the forecast period. The growing geriatric population & prevalence of chronic diseases coupled with increasing concern about needle stick injuries are expected to boost the wearable injectors market during the forecast period. In addition, rising demand for round-the-clock monitoring and the need to reduce healthcare costs are also expected to support market growth.
The growing geriatric population, coupled with rising prevalence of chronic diseases, such as cancer, diabetes, neurological disorders, hypertension, and age-related orthopedic disorders, is also expected to facilitate growth. The WHO estimates that the global population aged 60 years and above will rise from 841.0 million in 2013 to over 2.0 billion by 2050.
According to the WHO’s World Health Report 2002, around 2.0 million healthcare workers out of a total of 35.0 million, experience percutaneous exposure to infectious diseases every year. The report further states that worldwide, about 39.0% of patients suffering from Hepatitis C, 37.6% of those suffering from hepatitis B, and 4.4% of those suffering from HIV/AIDS are healthcare workers. Wearable injectors provide higher safety for patients and healthcare workers by eliminating risks related to conventional infusion and injection technology, such as drug preparation, needle insertion, covering, and needles’ disposal.
With technological advancements in injectors, a needle is never exposed to the patient. The needle is inserted after the injector is attached and the button is pressed. Once the drug is released, the needle automatically retracts and gets locked out, thereby enabling safe and convenient disposal of the system, and the patient is notified with tactile, audible, and visual signals. With the use of wearable injectors, there would be no needle stick injuries as compared to intravenous injectables and parenteral administration.
The rise in healthcare costs is one of the biggest concerns faced by developing and developed regions. These regions are struggling to develop cost-effective and quality care. With the help of wearable injectors, patients can self-administer the wearable injector at home subcutaneously. This is expected to reduce the number of visits to hospitals or other healthcare settings, thereby reducing healthcare expenses.
The types analyzed in this study include on-body and off-body wearable injectors. The on-body segment is expected to dominate the market owing to increased demand, as these patches are comfortable to wear on the skin (stomach). They are also water-resistant and convenient to use at home.
The benefits of on-body wearable injectors are:
Decreased healthcare costs (decrease number of visits to hospitals)
Lifecycle management (intravenous to subcutaneous)
Changes in dosage frequency
Flexible dosing
Automatic warming of refrigerated drug
The off-body segment is expected to register favorable growth over the forecast period as these devices eliminate risks, such as painful removal of devices, adhesive fitting issues to the skin, and skin sensitivity or irritation.
The technologies analyzed in this study include spring-based, motor-driven, rotary pump, expanding battery, and others. The spring-based segment is anticipated to dominate the market, owing to rising demand for adhesive patches, as these devices are user-friendly and enable patients to accurately deliver the drug subcutaneously by pressing one or more buttons on the device.
The motor-driven segment is expected to register comparatively higher CAGR over the forecast period, due to increasing customer demand for these devices as they are more convenient for use, as compared to others.
Applications analyzed in this study include oncology, infectious, cardiovascular, & autoimmune diseases, and others. The oncology segment is likely to dominate the market owing to the rising prevalence of cancer coupled with an increasing shift toward self-administration of medication among patients.
The autoimmune disease segment is expected to be the fastest-growing segment over the forecast period due to the rising prevalence of diabetes and the increasing adoption of wearable injectors due to their competitive advantage over insulin pumps.
The end-use segment is categorized into hospitals, clinics, home care, and others. The home care segment is expected to dominate, due to the rising preference for self-administration of medication and the increasing need to curb healthcare costs. In addition, growing demand for technologically developed drug delivery, which lowers hospitalization rate and requires minimal expertise, is expected to boost the market.
On the other hand, the hospital segment is expected to exhibit lucrative growth during the forecast period owing to the increased number of patients that require hospitalization. Also, the increasing number of hospitals across the globe is anticipated to drive the demand for this market.
North America held over 40.00% share in the wearable injectors market in 2016, owing to the rising prevalence of chronic & lifestyle-related diseases and the presence of sophisticated healthcare infrastructure. In addition, the local presence of major market players in the U.S., such as Becton, Dickinson and Company; Johnson & Johnson Services, Inc.; Unilife Corporation; SteadyMed Therapeutics, Inc.; Amgen, Inc.; and Enable Injections, is expected to boost the market.
Europe is also expected to hold a substantial market share during the forecast period due to the flourishing medical device industry in the UK, Germany, and France coupled with increasing avenues for market players in this region.
Asia Pacific is expected to register higher CAGR over the forecast period as compared to other regions, which can be attributed to favorable government initiatives for the use of medical devices such as wearable injectors, increasing geriatric population, and increasing healthcare expenditure in this region.
Some of the major players in this space include Becton, Dickinson and Company; Johnson & Johnson Services, Inc.; F. Hoffmann-La Roche Ltd.; Unilife Corporation; SteadyMed Therapeutics, Inc.; Amgen, Inc.; Insulet Corporation; Enable Injections; West Pharmaceutical Services, Inc.; and CeQur SA.
These players focus on growth strategies, such as new product launches, collaborations, partnerships, operational expansion, mergers & acquisitions, and patient awareness campaigns. For instance, in June 2014, SteadyMed Therapeutics, Inc. partnered with Bespak Europe Ltd., a European manufacturer of medical devices, to develop and manufacture Trevyent (an injector with PatchPump-based platform that works on an expanding battery to take the drug out of a flexible primary drug container).
Report Attribute |
Details |
Market size value in 2020 |
USD 5.2 billion |
Revenue forecast in 2025 |
USD 11.3 billion |
Growth Rate |
CAGR of 16.4% from 2017 to 2025 |
Base year for estimation |
2016 |
Historical data |
2014 - 2015 |
Forecast period |
2017 - 2025 |
Quantitative units |
Revenue in USD million and CAGR from 2017 to 2025 |
Report coverage |
Revenue forecast, company share, competitive landscape, growth factors and trends |
Segments covered |
Type, technology, application, end use, region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
Country scope |
U.S.; Canada; UK; Germany; Japan; China; France; Brazil; Mexico; South Africa |
Key companies profiled |
Becton, Dickinson and Company; Johnson & Johnson Services, Inc.; F. Hoffmann-La Roche Ltd.; Unilife Corporation; SteadyMed Therapeutics, Inc.; Amgen, Inc.; Insulet Corporation; Enable Injections; West Pharmaceutical Services, Inc.; CeQur SA. |
Customization scope |
Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2014 to 2025. For the purpose of this study, Grand View Research, Inc. has segmented the global wearable injectors market on the basis of type, technology, application, end use, and region:
Type Outlook (Revenue, USD Million, 2014 - 2025)
On-body
Off-body
Technology Outlook (Revenue, USD Million, 2014 - 2025)
Spring-based
Motor-driven
Rotary Pump
Expanding Battery
Other
Application Outlook (Revenue, USD Million, 2014 - 2025)
Oncology
Infectious Disease
Cardiovascular Disease
Autoimmune Disease
Other
End-use Outlook (Revenue, USD Million, 2014 - 2025)
Hospital
Clinic
Home Care
Other
Regional Outlook (Revenue, USD Million, 2014 - 2025)
North America
The U.S.
Canada
Europe
Germany
The U.K.
France
Asia Pacific
Japan
China
Latin America
Brazil
Mexico
The Middle East and Africa (MEA)
South Africa
b. The global wearable injectors market size was estimated at USD 4.5 billion in 2019 and is expected to reach USD 5.2 billion in 2020.
b. The global wearable injectors market is expected to grow at a compound annual growth rate of 16.4% from 2017 to 2025 to reach USD 11.3 billion by 2025.
b. North America dominated the wearable injectors market with a share of 41.3% in 2019. This is attributable to the rising prevalence of chronic & lifestyle-related diseases and the presence of sophisticated healthcare infrastructure.
b. Some key players operating in the wearable injectors market include Becton, Dickinson and Company; Johnson & Johnson Services, Inc.; F. Hoffmann-La Roche Ltd.; Unilife Corporation; SteadyMed Therapeutics, Inc.; Amgen, Inc.; Insulet Corporation; Enable Injections; West Pharmaceutical Services, Inc.; and CeQur SA.
b. Key factors that are driving the market growth include rising demand for round-the-clock monitoring, Increasing concern over the hazards related to needlestick injuries, and technological developments in wearable injectors.
This report has a service guarantee. We stand by our report quality.
We are in compliance with GDPR & CCPR norms. All interactions are confidential.
Design an exclusive study to serve your research needs.
Get your queries resolved from an industry expert.
"The quality of research they have done for us has been excellent..."
With Covid-19 infections rising globally, the apprehension regarding a shortage of essential life-saving devices and other essential medical supplies in order to prevent the spread of this pandemic and provide optimum care to the infected also widens. In addition, till a pharmacological treatment is developed, ventilators act as a vital treatment preference for the COVID-19 patients, who may require critical care. Moreover, there is an urgent need for a rapid acceleration in the manufacturing process for a wide range of test-kits (antibody tests, self-administered, and others). The report will account for Covid19 as a key market contributor.